“The take-home message of the Bausch Launch Event: same dermatology. New biological target: the skin microbiome.”

“Protocols are evolving from antibiotic-centred decision trees to ecosystem-based care pathways. This shift isn’t just regulatory. It’s biological.”

“Many of today’s inflammatory and recurrent skin conditions are not caused by too many microbes, but by losing contact with the right ones. Understanding these old friends is reshaping how we think about skin health, treatment strategies and the future of microbiome‑based care.”

“Fungal skin conditions, from athlete’s foot to skin fold infections and recurring fungal irritations, affect millions across all age groups.”

“A thought-provoking exhibition at DE SINGEL in Antwerp that challenges the way we think about bacteria, health and the environments we live in.”

“Over four weeks, 78 testers used complete routines from the ATO (atopic dermatitis) or ACN (acne) lines and evaluated each product on effectiveness, feel, composition and overall satisfaction.”

“From Belgian biotech to international growth: Bausch Health and YUN expand to Mexico and across EMEA.”

“Antimicrobial resistance remains a growing global challenge, including in veterinary medicine.”

“The future of skin health is not more destruction. It is precision with preservation.”

“In a healthy vaginal microbiome, Lactobacilli dominate not by coincidence, but by function.”

“Within eighteen months, our YUN products will reach two billion people worldwide,” says our founder & CEO Tom Verlinden.

“Mild is not the same as microbiome-safe. Our scoring system shows the difference. Microbiome safety is measurable and the bacteria tell us the truth.”